• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

    4/13/26 1:55:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email

    REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and unsolicited proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group") to acquire all of the outstanding shares of Seer's Class A common stock for $2.25 per share in cash plus a contingent value right (the "Proposal").

    Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Seer Board of Directors (the "Board") will carefully review and consider the Proposal to determine the course of action that it believes is in the best interests of the Company and all Seer stockholders.

    In addition, Radoff-JEC Group has nominated three director candidates to stand for election to the Board at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). The Corporate Governance and Nominating Committee of the Board will review the proposed nominees in accordance with the Company's bylaws.

    The Board will present its formal recommendation regarding the Radoff-JEC Group's director nominations in the Company's definitive proxy statement, to be filed with the Securities and Exchange Commission and mailed to all stockholders eligible to vote at the 2026 Annual Meeting. The date of the 2026 Annual Meeting has not yet been announced.

    No stockholder action is required at this time.

    Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.

    About Seer, Inc.

    Seer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

    For more information, please email us at [email protected].

    Additional Information and Where to Find It

    Seer, its directors and certain executive officers are participants in the solicitation of proxies from stockholders in connection with Seer's 2026 Annual Meeting of Stockholders (the "Annual Meeting"). Seer plans to file a proxy statement (the "2026 Proxy Statement") with the Securities and Exchange Commission (the "SEC") in connection with the solicitation of proxies for the Annual Meeting.

    Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Deep Nishar, Isaac Ro and Nicolas Roelofs, all of whom are members of Seer's board of directors, and David Horn, Seer's president and chief financial officer, are participants in Seer's solicitation. Additional information regarding such participants, including their direct or indirect interests, by security holdings or otherwise, will be included in the 2026 Proxy Statement and other relevant documents to be filed by Seer with the SEC in connection with the Annual Meeting. Information relating to the foregoing can also be found in Seer's definitive proxy statement for its 2025 Annual Meeting of Stockholders (the "2025 Proxy Statement"), which was filed with the SEC on May 28, 2025, and is available here. Particular attention is directed to the sections of the 2025 Proxy Statement captioned "Board of Directors and Corporate Governance," "Executive Compensation," "Named Executive Officer Compensation Overview," "Security Ownership of Certain Beneficial Owners and Management" and "Certain Relationships, Related Party and Other Transactions." To the extent that holdings of such participants in Seer's securities have changed since the amounts printed in the 2025 Proxy Statement, such changes have been reflected on the following filings: for Mr. Farokhzad, on May 22, 2025, August 21, 2025, November 21, 2025, December 11, 2025, February 5, 2026, and February 19, 2026; for Ms. Gulyani, on July 9, 2025; for Mr. Langer, on July 9, 2025; for Mr. McGuire, on July 9, 2025 and December 11, 2025; for Mr. Nishar, on June 16, 2025 and July 9, 2025; for Mr. Ro, on September 3, 2025; for Mr. Roelofs, on July 9, 2025; and for Mr. Horn, on May 22, 2025; August 21, 2025; November 21, 2025, February 5, 2026, and February 19, 2026.

    Promptly after filing its definitive 2026 Proxy Statement with the SEC, Seer will mail the definitive 2026 Proxy Statement and a BLUE proxy card to each stockholder entitled to vote at the Annual Meeting. STOCKHOLDERS ARE URGED TO READ THE 2026 PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT SEER WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, Seer's proxy statement (in both preliminary and definitive form), any amendments or supplements thereto, and any other relevant documents filed by Seer with the SEC in connection with the Annual Meeting at the SEC's website, which is located here. Copies of Seer's definitive 2026 Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by Seer with the SEC in connection with the Annual Meeting will also be available, free of charge, at Seer's website, which is located here, or by writing to Investor Relations, Seer, Inc., 3800 Bridge Parkway, Suite 102, Redwood City, CA 94065.

    Forward Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions to be taken by the Board. These and other risks are described more fully in Seer's filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Media Contact:

    Patrick Schmidt

    [email protected]

    Joele Frank, Wilkinson Brimmer Katcher

    Eric Brielmann / Joseph Sala

    (212) 355-4449

    Investor Contact:

    Marissa Bych

    [email protected]



    Primary Logo

    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    SEC Filings

    View All

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    4/13/26 4:56:09 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Seer, Inc. (0001726445) (Filer)

    4/13/26 4:47:50 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DFAN14A filed by Seer Inc.

    DFAN14A - Seer, Inc. (0001726445) (Subject)

    4/13/26 4:39:49 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by JP Morgan with a new price target

    JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

    8/11/22 6:17:02 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $15,447 worth of shares (7,743 units at $1.99), decreasing direct ownership by 2% to 501,262 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/19/26 4:11:51 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO AND CHAIR Farokhzad Omid sold $48,646 worth of shares (24,385 units at $1.99), decreasing direct ownership by 0.72% to 3,349,064 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/19/26 4:06:45 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CFO Horn David R. was granted 79,000 shares, increasing direct ownership by 18% to 509,005 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/5/26 6:54:29 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

    REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and unsolicited proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group") to acquire all of the outstanding shares of Seer's Class A common stock for $2.25 per share in cash plus a contingent value right (the "Proposal"). Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Seer Board of Directors (the "Board") will carefully

    4/13/26 1:55:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.

    Proposal Provides Stockholders $2.25 per Share in Cash, a 33% Premium to the Most Recent Closing Price, as Well as Potential Additional Value from the Sale of Seer's Assets via a Contingent Value Right Proposal Provides Seer Stockholders Immediate and Significant Value While Avoiding Further Value Destruction from Continued Abysmal Operating Results Nominates Three Highly Qualified Director Candidates – Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini – for Election at Upcoming Annual Meeting Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc.

    4/13/26 8:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples

    REDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph® Product Suite, has been selected as the mass spectrometry-based proteomic workflow to deeply profile the plasma proteome in 10,000 participants from PRECISE-SG100K. This unbiased proteomics data set will be combined with data from Thermo Fisher Scientific's Olink® Reveal and Thermo Scientific Orbitrap Astral™ mass spectrometers, utilized on the same set of samples to enhance the proteomic insights available to researchers. PRECISE-SG100K is a landmark, multi-ancestry population-scale cohort of approx

    4/9/26 8:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

    REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

    3/16/22 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th

    2/5/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials